S&P 500   3,629.86 (-0.15%)
DOW   29,905.45 (-0.47%)
QQQ   296.03 (+0.53%)
AAPL   116.04 (+0.76%)
MSFT   213.58 (-0.13%)
FB   275.59 (-0.48%)
GOOGL   1,768.17 (+0.24%)
AMZN   3,168.20 (+1.61%)
TSLA   572.22 (+3.03%)
NVDA   528.28 (+1.92%)
BABA   276.39 (-1.28%)
CGC   26.98 (+0.04%)
GE   10.48 (+0.29%)
MU   63.37 (-0.91%)
AMD   87.08 (+2.36%)
T   28.97 (-0.89%)
NIO   52.89 (-1.16%)
F   9.05 (-4.23%)
ACB   8.86 (-4.01%)
NFLX   483.20 (+0.07%)
GILD   59.74 (-0.85%)
BA   218.96 (+0.22%)
DIS   148.71 (-1.84%)
S&P 500   3,629.86 (-0.15%)
DOW   29,905.45 (-0.47%)
QQQ   296.03 (+0.53%)
AAPL   116.04 (+0.76%)
MSFT   213.58 (-0.13%)
FB   275.59 (-0.48%)
GOOGL   1,768.17 (+0.24%)
AMZN   3,168.20 (+1.61%)
TSLA   572.22 (+3.03%)
NVDA   528.28 (+1.92%)
BABA   276.39 (-1.28%)
CGC   26.98 (+0.04%)
GE   10.48 (+0.29%)
MU   63.37 (-0.91%)
AMD   87.08 (+2.36%)
T   28.97 (-0.89%)
NIO   52.89 (-1.16%)
F   9.05 (-4.23%)
ACB   8.86 (-4.01%)
NFLX   483.20 (+0.07%)
GILD   59.74 (-0.85%)
BA   218.96 (+0.22%)
DIS   148.71 (-1.84%)
S&P 500   3,629.86 (-0.15%)
DOW   29,905.45 (-0.47%)
QQQ   296.03 (+0.53%)
AAPL   116.04 (+0.76%)
MSFT   213.58 (-0.13%)
FB   275.59 (-0.48%)
GOOGL   1,768.17 (+0.24%)
AMZN   3,168.20 (+1.61%)
TSLA   572.22 (+3.03%)
NVDA   528.28 (+1.92%)
BABA   276.39 (-1.28%)
CGC   26.98 (+0.04%)
GE   10.48 (+0.29%)
MU   63.37 (-0.91%)
AMD   87.08 (+2.36%)
T   28.97 (-0.89%)
NIO   52.89 (-1.16%)
F   9.05 (-4.23%)
ACB   8.86 (-4.01%)
NFLX   483.20 (+0.07%)
GILD   59.74 (-0.85%)
BA   218.96 (+0.22%)
DIS   148.71 (-1.84%)
S&P 500   3,629.86 (-0.15%)
DOW   29,905.45 (-0.47%)
QQQ   296.03 (+0.53%)
AAPL   116.04 (+0.76%)
MSFT   213.58 (-0.13%)
FB   275.59 (-0.48%)
GOOGL   1,768.17 (+0.24%)
AMZN   3,168.20 (+1.61%)
TSLA   572.22 (+3.03%)
NVDA   528.28 (+1.92%)
BABA   276.39 (-1.28%)
CGC   26.98 (+0.04%)
GE   10.48 (+0.29%)
MU   63.37 (-0.91%)
AMD   87.08 (+2.36%)
T   28.97 (-0.89%)
NIO   52.89 (-1.16%)
F   9.05 (-4.23%)
ACB   8.86 (-4.01%)
NFLX   483.20 (+0.07%)
GILD   59.74 (-0.85%)
BA   218.96 (+0.22%)
DIS   148.71 (-1.84%)
Log in
NYSE:HUM

Humana Stock Forecast, Price & News

$401.12
-7.07 (-1.73 %)
(As of 11/25/2020 01:44 PM ET)
Add
Compare
Today's Range
$400.16
Now: $401.12
$411.67
50-Day Range
$396.75
MA: $426.44
$452.01
52-Week Range
$208.25
Now: $401.12
$474.70
Volume19,774 shs
Average Volume1.03 million shs
Market Capitalization$53.08 billion
P/E Ratio12.86
Dividend Yield0.61%
Beta0.94
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; financial protection products; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE South Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2019, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
Read More
Humana logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 1.7Insider Behavior: 1.7Valuation: 3.1 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.46 out of 5 stars


Industry, Sector and Symbol

Industry Hospital & medical service plans
Sub-IndustryManaged Health Care
SectorMedical
CUSIP44485910
Phone502-580-1000
Employees46,000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$64.89 billion
Cash Flow$19.98 per share
Book Value$119.19 per share

Profitability

Net Income$2.71 billion

Miscellaneous

Market Cap$53.08 billion
Next Earnings Date2/3/2021 (Estimated)
OptionableOptionable
$401.12
-7.07 (-1.73 %)
(As of 11/25/2020 01:44 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HUM News and Ratings via Email

Sign-up to receive the latest news and ratings for HUM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Humana (NYSE:HUM) Frequently Asked Questions

How has Humana's stock price been impacted by Coronavirus (COVID-19)?

Humana's stock was trading at $328.22 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HUM shares have increased by 22.1% and is now trading at $400.91.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Humana?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Humana in the last year. There are currently 6 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Humana
.

What stocks does MarketBeat like better than Humana?

Wall Street analysts have given Humana a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Humana wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Humana's next earnings date?

Humana is scheduled to release its next quarterly earnings announcement on Wednesday, February 3rd 2021.
View our earnings forecast for Humana
.

How were Humana's earnings last quarter?

Humana Inc. (NYSE:HUM) posted its quarterly earnings data on Tuesday, November, 3rd. The insurance provider reported $3.08 earnings per share for the quarter, beating the Zacks' consensus estimate of $2.81 by $0.27. The insurance provider earned $20.08 billion during the quarter, compared to analyst estimates of $18.59 billion. Humana had a net margin of 5.58% and a return on equity of 22.74%. Humana's quarterly revenue was up 23.6% compared to the same quarter last year. During the same quarter last year, the business earned $5.03 earnings per share.
View Humana's earnings history
.

How often does Humana pay dividends? What is the dividend yield for Humana?

Humana announced a quarterly dividend on Tuesday, November 3rd. Investors of record on Thursday, December 31st will be paid a dividend of $0.625 per share on Friday, January 29th. This represents a $2.50 dividend on an annualized basis and a yield of 0.62%. The ex-dividend date of this dividend is Wednesday, December 30th.
View Humana's dividend history
.

What guidance has Humana issued on next quarter's earnings?

Humana issued an update on its FY20 earnings guidance on Tuesday, November, 3rd. The company provided EPS guidance of $18.50-18.75 for the period, compared to the Thomson Reuters consensus estimate of $18.76.

What price target have analysts set for HUM?

20 equities research analysts have issued 12-month price targets for Humana's stock. Their forecasts range from $358.00 to $510.00. On average, they anticipate Humana's share price to reach $449.68 in the next year. This suggests a possible upside of 12.2% from the stock's current price.
View analysts' price targets for Humana
.

Are investors shorting Humana?

Humana saw a increase in short interest in the month of October. As of October 15th, there was short interest totaling 1,710,000 shares, an increase of 18.8% from the September 30th total of 1,440,000 shares. Based on an average daily volume of 609,500 shares, the days-to-cover ratio is currently 2.8 days. Approximately 1.3% of the company's stock are sold short.
View Humana's Short Interest
.

Who are some of Humana's key competitors?

What other stocks do shareholders of Humana own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Humana investors own include UnitedHealth Group (UNH), NVIDIA (NVDA), The Walt Disney (DIS), Visa (V), Mastercard (MA), Alibaba Group (BABA), The Boeing (BA), salesforce.com (CRM), Johnson & Johnson (JNJ) and JPMorgan Chase & Co. (JPM).

Who are Humana's key executives?

Humana's management team includes the following people:
  • Mr. Bruce Dale Broussard, Pres, CEO & Director (Age 58, Pay $5.43M)
  • Mr. Brian Andrew Kane, Chief Financial Officer (Age 47, Pay $2.12M)
  • Mr. Timothy S. Huval, Chief Admin. Officer (Age 54, Pay $1.8M)
  • Mr. T. Alan Wheatley, Segment Pres of Retail (Age 51, Pay $1.64M)
  • Dr. William Kevin Fleming Pharm.D., PharmD, RPh, Segment Pres of Clinical & Pharmacy Solutions (Age 52, Pay $1.5M)
  • Ms. Cynthia Hillebrand Zipperle, Sr. VP, Chief Accounting Officer & Controller (Age 57)
  • Mr. Sam M. Deshpande, Chief Technology & Risk Officer (Age 55)
  • Ms. Amy K. Smith, VP of Investor Relations
  • Mr. Joseph C. Ventura, Chief Legal Officer (Age 43)
  • Amy Fry, Sr. VP of Corp. Communications

What is Humana's stock symbol?

Humana trades on the New York Stock Exchange (NYSE) under the ticker symbol "HUM."

Who are Humana's major shareholders?

Humana's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (8.95%), State Street Corp (4.53%), Jennison Associates LLC (1.30%), Newport Trust Co (1.13%), Wells Fargo & Company MN (0.69%) and UBS Asset Management Americas Inc. (0.58%). Company insiders that own Humana stock include Brian P Leclaire, Christopher H Hunter, David A Jr/Ky Jones, Elizabeth D Bierbower, Heidi S Margulis, James J /Ky Obrien, Roy A Beveridge, Timothy Alan Wheatley and Timothy S Huval.
View institutional ownership trends for Humana
.

Which major investors are selling Humana stock?

HUM stock was sold by a variety of institutional investors in the last quarter, including AJO LP, AQR Capital Management LLC, State of Tennessee Treasury Department, Acadian Asset Management LLC, JPMorgan Chase & Co., Artemis Investment Management LLP, State Street Corp, and CI Investments Inc.. Company insiders that have sold Humana company stock in the last year include David A Jr/Ky Jones, Elizabeth D Bierbower, James J /Ky Obrien, Timothy Alan Wheatley, and Timothy S Huval.
View insider buying and selling activity for Humana
.

Which major investors are buying Humana stock?

HUM stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, BlackRock Inc., Polar Capital LLP, Polar Capital LLP, Jupiter Asset Management Ltd., Ceredex Value Advisors LLC, BNP Paribas Arbitrage SA, and UBS Asset Management Americas Inc..
View insider buying and selling activity for Humana
.

How do I buy shares of Humana?

Shares of HUM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Humana's stock price today?

One share of HUM stock can currently be purchased for approximately $400.91.

How big of a company is Humana?

Humana has a market capitalization of $53.06 billion and generates $64.89 billion in revenue each year. The insurance provider earns $2.71 billion in net income (profit) each year or $17.87 on an earnings per share basis. Humana employs 46,000 workers across the globe.

What is Humana's official website?

The official website for Humana is www.humana.com.

How can I contact Humana?

Humana's mailing address is 500 West Main Street, LOUISVILLE KY, 40202. The insurance provider can be reached via phone at 502-580-1000 or via email at [email protected]

This page was last updated on 11/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.